Not actual patient.
PEDMARK is a prescription medicine used to decrease the risk of hearing loss in people 1 month of age and older who are receiving cisplatin for
solid tumors (cancer) that have not spread to other parts of the body.
Not actual patient.
Not actual patient.
Currently, most people who receive platinum-based chemotherapy, such as cisplatin, develop hearing loss.
What is cisplatin-induced hearing loss?
Not actual patient.
These recommendations are not consistent with the FDA indication. Always refer to the PEDMARK Prescribing Information and Instructions for Use.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Adolescent and Young Adult (AYA) Oncology recommends sodium thiosulfate (PEDMARK) as a preventative treatment option to reduce CIO in pediatric/AYA patients with localized, nonmetastatic solid tumors.
*NCCN Guidelines® define an adolescent or young adult (AYA) oncology patient as an individual between 15 and 39 years.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
CIO=cisplatin-induced ototoxicity; NCCN=National Comprehensive Cancer Network.
Not actual patient.
In clinical studies, PEDMARK significantly reduced the number of people who had hearing loss due to cisplatin-based cancer treatment when compared with those who did not receive PEDMARK.
Not actual patient.
Not actual patient.
A total of 232 patients up to the age of 18 years received PEDMARK in the clinical studies.
Not actual patient.
No generic approved product exists or can be directly compared; PEDMARK is not substitutable with any other STS formulation.
Fennec HEARS™ is the single source for both financial and patient support. Call 1-833-7PEDMARK.
Find helpful tools and resources.
Please see full Prescribing Information, including Patient Information, for PEDMARK.
PEDMARK is a prescription medicine used to decrease the risk of hearing loss in children 1 month of age and older who are receiving cisplatin for solid tumors (cancer) that have not spread to other parts of the body.
It is not known if PEDMARK is safe and effective when given after cisplatin infusions longer than 6 hours.
It is not known if PEDMARK is safe and effective in children less than 1 month of age. PEDMARK is not recommended in children younger than 1 month of age.